The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

An experimental pill developed by Johnson & Johnson and Protagonist Therapeutics significantly cleared skin in most people ...

Today, a brief rundown of news involving Astellas and Cytokinetics, as well as updates from Cybin, Neurogene and Novartis ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Chinese Hamster Ovary (CHO) cells have played a pivotal role in the production of biopharmaceutical proteins since their ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...